key: cord-0882770-fzap5w5b
authors: Rezazadeh Ardabili, Ashkan; Creemers, Rob H; van Bodegraven, Adriaan A
title: COVID-19 in the IBD population: The need for correct nomenclature
date: 2020-10-29
journal: J Crohns Colitis
DOI: 10.1093/ecco-jcc/jjaa222
sha: 8863fc00389f7d2ef66cf6545e335ed864500eab
doc_id: 882770
cord_uid: fzap5w5b

nan

A c c e p t e d M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjaa222

To the editor,

We read with great interest the article by Attauabi et al. in which they describe COVID-19 prevalence and outcomes in IBD patients in a Danish population-based cohort. 1 We commend the authors for establishing a population-based setting as this adds to a better understanding of potential risk factors and implications of COVID-19 for the IBD population.

However, we also would like to emphasise the importance of using correct nomenclature. Initially, as testing capacity was limited, predominantly people with COVID-19 associated symptoms were tested for SARS-CoV-2 infection. As a result, SARS-CoV-2 infection was used as a surrogate for COVID-19 in most studies. The indication for SARS-CoV-2 testing has changed since the beginning of the pandemic. We find that expansion of testing capacity has led to SARS-CoV-2 testing in people without symptoms, for instance in the context of contact research. This has also been acknowledged by Attauabi et al. in their article. Moreover, a recent study by Norsa et al. found that more than 1 in five (21%) IBD patients on biologic treatment in the Bergamo region, which was the European epicentre of SARS-CoV-2 infections, had been exposed to SARS-CoV-2. More than half of those patients (58%) were asymptomatic. 2 infections for IBD patients rather than the true prevalence of COVID-19, the presented data and the population-based approach are still very informative and valuable. In order to be able to identify international differences, ensure generalizability, and learn from each other's data in this ongoing pandemic, we believe that epidemiological data should be presented in a standard format, preferably based on the internationally accepted nomenclature.

Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease -A Danish prospective population-based cohort study

Asymptomatic SARS-CoV-2 infection in patients with inflammatory bowel disease under biologic treatment. Gastroenterology

Naming the coronavirus disease (COVID-19) and the virus that causes it

A c c e p t e d M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjaa222 References: